In recent clinical studies, it has been identified that treatments with IL-6R antagonists can attenuate pulmonary vascular remodeling that prevents or reverses the development of PAH in MCT and SU5416/hypoxia rat models [81,90]. The gene discussed is IL6R; the disease is pulmonary arterial hypertension.